| Patents for C12N 15 - Mutation or genetic engineering; Dna or rna concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (402,210) |
|---|
| 07/26/2001 | WO2001053473A2 Methods for amplifying genetic material and uses thereof |
| 07/26/2001 | WO2001053470A2 Nucleic acid and amino acid sequences encoding a de novo dna methyltransferase |
| 07/26/2001 | WO2001053469A2 Phosphatases |
| 07/26/2001 | WO2001053468A2 Lipid metabolism enzymes and polynucleotides encoding them |
| 07/26/2001 | WO2001053467A1 Recombinant flaviviruses and methods of use thereof |
| 07/26/2001 | WO2001053462A1 Liver tissue source |
| 07/26/2001 | WO2001053461A1 Multipotent neural stem cells from peripheral tissues and uses thereof |
| 07/26/2001 | WO2001053459A1 Process for producing l-lysine |
| 07/26/2001 | WO2001053452A2 Regeneration and genetic transformation of acacia mangium |
| 07/26/2001 | WO2001053355A1 An in vivo screen using chemical inducers of dimerization |
| 07/26/2001 | WO2001053353A2 Recombinant antibodies to human interkleukin-1 beta |
| 07/26/2001 | WO2001053352A2 Sperm specific proteins |
| 07/26/2001 | WO2001053351A2 Apoptin bindendes protein |
| 07/26/2001 | WO2001053348A2 Human polypeptides related to the vanilloid and trp families of cation channel proteins and nucleic acids encoding them |
| 07/26/2001 | WO2001053347A2 Nphs2 gene involved in the cortico-resistant neprhotic syndrome, protein encoded by said gene and diagnostic and therapeutic uses |
| 07/26/2001 | WO2001053346A1 Human cystine knot polypeptide |
| 07/26/2001 | WO2001053345A1 Vegf148 isoform, a truncated splice variant of vegf. vegf heterodimers and therapeutical uses thereof |
| 07/26/2001 | WO2001053344A2 Chondromodulin-i related peptide |
| 07/26/2001 | WO2001053343A1 Human polynucleotides, polypeptides, and antibodies |
| 07/26/2001 | WO2001053341A1 A new polypeptide-human zinc finger protein 13 and the polynucleotide encoding it |
| 07/26/2001 | WO2001053340A2 Transgenic mouse model of human neurodegenerative disease |
| 07/26/2001 | WO2001053339A2 Egg specific surface proteins |
| 07/26/2001 | WO2001053338A2 Cbp86, a sperm specific protein |
| 07/26/2001 | WO2001053337A1 Human 7 transmembrane receptor axor33 |
| 07/26/2001 | WO2001053333A1 Methods for the purification and aqueous fiber spinning of spider silks and other structural proteins |
| 07/26/2001 | WO2001053326A1 Methods and materials relating to phospholipase-like polypeptides and polynucleotides |
| 07/26/2001 | WO2001053324A2 Novel haptotactic peptides |
| 07/26/2001 | WO2001053323A2 Plants tolerant of environmental stress conditions, methods of generating same and novel polynucleotide sequence utilized thereby |
| 07/26/2001 | WO2001053317A1 Antisense modulation of macrophage migration inhibitory factor expression |
| 07/26/2001 | WO2001053314A1 Antisense modulation of daxx expression |
| 07/26/2001 | WO2001053313A1 Antisense modulation of smad7 expression |
| 07/26/2001 | WO2001053311A1 Antisense modulation of peroxisome proliferator-activated receptor gamma expression |
| 07/26/2001 | WO2001053310A1 Antisense modulation of caspase 3 expression |
| 07/26/2001 | WO2001053309A1 Methods and compositions for bioremediation |
| 07/26/2001 | WO2001053306A2 Manufacture of five-carbon sugars and sugar alcohols |
| 07/26/2001 | WO2001053253A1 Method of purifying amide compound |
| 07/26/2001 | WO2001052987A1 Contacting device |
| 07/26/2001 | WO2001052904A2 Pharmaceutical compositions and methods of treatment based on vegf antisense oligonucleotides |
| 07/26/2001 | WO2001052903A1 Method for nucleic acid transfection of cells |
| 07/26/2001 | WO2001052902A1 Antisense modulation of inducible nitric oxide synthase expression |
| 07/26/2001 | WO2001052901A1 Drugs for gene therapy |
| 07/26/2001 | WO2001052892A2 Jak/stat pathway inhibitors and the uses thereof |
| 07/26/2001 | WO2001052886A1 Prime-boost vaccination strategy |
| 07/26/2001 | WO2001052874A2 Intra-tumoral administration of il-12 encoding nucleic acid molecules |
| 07/26/2001 | WO2001052868A1 Combinations for treating neoplasms |
| 07/26/2001 | WO2001052865A1 Antisense modulation of glycogen synthase kinase 3 alpha expression |
| 07/26/2001 | WO2001052864A1 Antisense modulation of cot oncogene expression |
| 07/26/2001 | WO2001052863A1 Antisense modulation of mekk2 expression |
| 07/26/2001 | WO2001052862A1 Antisense modulation of glycogen synthase kinase 3 beta expression |
| 07/26/2001 | WO2001052643A1 Transgenic goat producing milk containing human granulocyte-colony stimulating factor |
| 07/26/2001 | WO2001052642A1 Method of transferring mutant mitochondrial dna into genital cells |
| 07/26/2001 | WO2001052641A1 Non-human mammal with a modified glucocorticoid receptor and a modified c-fos |
| 07/26/2001 | WO2001052620A2 Methods and compositions to modulate expression in plants |
| 07/26/2001 | WO2001052612A2 Method for isolating proteins or protein and nucleic acid associations, and resulting complexes of particles and proteins |
| 07/26/2001 | WO2001046401A8 Embryonic or stem-like cells produced by cross species nuclear transplantation |
| 07/26/2001 | WO2001034206A8 Nucleic acid-containing complex |
| 07/26/2001 | WO2001018212A3 Mycobacterium paratuberculosis-specific antigens and their diagnostic uses |
| 07/26/2001 | WO2001014415A3 Egfh2 genes and gene products |
| 07/26/2001 | WO2001010902A8 Nucleoc acids and secreted polypeptides encoded thereby |
| 07/26/2001 | WO2001007590A3 Chimeric genes for plastid expression |
| 07/26/2001 | WO2001007584A8 Controlled electroporation and mass transfer across cell membranes |
| 07/26/2001 | WO2001007566A3 Phage-resistant microorganisms and genetic determinants of phage resistance |
| 07/26/2001 | WO2001004285A3 Maize msi polynucleotides and methods of use |
| 07/26/2001 | WO2001004264A3 Atherosclerosis-associated genes |
| 07/26/2001 | WO2001004148A9 Donor strand complemented pilin and adhesin broad-based vaccines |
| 07/26/2001 | WO2001002583A3 Orynebacterium glutamicum genes encoding phosphoenolpyruvate: sugar phosphotransferase system proteins |
| 07/26/2001 | WO2001001748A3 Peptide compounds that bind her2 |
| 07/26/2001 | WO2001000876A9 Nanoparticles having oligonucleotides attached thereto and uses therefor |
| 07/26/2001 | WO2001000784A3 Compound derived from an offset orf of the ice gene |
| 07/26/2001 | WO2000078939A3 Vectors for the treatment of tumors by gene therapy |
| 07/26/2001 | WO2000078933A3 Novel calpains and their use |
| 07/26/2001 | WO2000078799A3 Mlo-genes controlling diseases |
| 07/26/2001 | WO2000075336A3 Polyepitopic proteinic fragments of e6 and e7 hpv proteins, production and use thereof in vaccines |
| 07/26/2001 | WO2000075324A9 Recombinant prion-like genes and proteins and materials and methods comprising same |
| 07/26/2001 | WO2000075180A3 Peptides for vaccinating against human cmv |
| 07/26/2001 | WO2000071741A9 Dna encoding a human subunit of the 5-ht3 serotonin receptor |
| 07/26/2001 | WO2000070341A3 Methods, pharmaceutical formulations and kits for identification of subjects at risk for cancer |
| 07/26/2001 | WO2000066156A8 Death domain containing receptor 5 |
| 07/26/2001 | WO2000065037A3 Maize npr1 polynucleotides and methods of use |
| 07/26/2001 | WO2000060079A9 New members of tnf and tnfr families |
| 07/26/2001 | WO2000055194A9 Tuberculosis antigens and methods of use therefor |
| 07/26/2001 | WO2000052155A3 Recombination of insertion modified nucleic acids |
| 07/26/2001 | WO2000045176A3 METHOD OF IDENTIFYING N-TERMINAL proBNP |
| 07/26/2001 | WO2000042182A9 Mammalian cortexin-like proteins and polynucleotides encoding the same |
| 07/26/2001 | WO2000041566A9 Regulation of endogenous gene expression in cells using zinc finger proteins |
| 07/26/2001 | WO2000040616A9 METHODS OF ELICITING BROADLY NEUTRALIZING ANTIBODIES TARGETING HIV-1 gp41 |
| 07/26/2001 | WO2000037683A9 HIGH THROUGHPUT ASSAY SYSTEM FOR MONITORING ESTs |
| 07/26/2001 | WO2000026388A9 Novel expression cassette for expressing genes in plant seed |
| 07/26/2001 | WO2000017361A3 Interferon-epsilon |
| 07/26/2001 | US20010009959 Polynucleotide vaccine formula against canine pathologies, in particular respiratory and digestive pathologies |
| 07/26/2001 | US20010009905 Adipocyte Complement-Related Protein encoded polypeptides, used in therapy and diagnosis, cell proliferation, cell death, energy homestasis; treatment of cancers, obesity, diabetes, heart disease, immunity |
| 07/26/2001 | US20010009904 Process of delivering a polynucleotide to a cell via the vascular system |
| 07/26/2001 | US20010009900 Breast cancer, increase insulin receptor phosphorylation in Type II diabetics |
| 07/26/2001 | US20010009772 Transfecting cell with first polynucleotide comprising retroviral genome operably linked to first inducible transcription regulation element wherein retroviral genome is defective for self-replication, second, third polynucleotides |
| 07/26/2001 | US20010009768 Polynucleotides encoding cytokine designated LERK-5 |
| 07/26/2001 | US20010009766 Dna encoding galanin galr3 receptors and uses thereof |
| 07/26/2001 | US20010009763 Array of a plurality of particles having probes, respectively, fixed thereon, said probes being capable of binding to different target substances to be examined, respectively |
| 07/26/2001 | US20010009761 Methods and oligonucleotides for detecting nucleic acid sequence variations |
| 07/26/2001 | US20010009760 Reducing background signals in nucleic acid hybridization assays by using an oligonucleotide labelled with a quenchable dipyrrolometheneboron difluoride dye |
| 07/26/2001 | US20010009669 Inactive flavivirus such as tick-born encephalitis (TBE) virus, an immunogenic component bonded to the flavivirus or adsorbed therewith |